Published on
Oct 23, 2026
Ultomiris Wins Accelerated FDA Approval for IgA Nephropathy After Trial Showed 43% Greater Drop in Urine Protein
The Food and Drug Administration has granted accelerated approval to Ultomiris, also known as ravulizumab, to reduce protein in the urine of adults with primary IgA nephropathy who are at risk of disease progression, AstraZeneca announced Oct. 21. In a …
Source:
Medical Daily
-
Indeterminate
